SEC Stock Data Quick Answer Aclaris Therapeutics, Inc. reported Long-Term Debt of $10.65 million for fiscal year 2020. Aclaris Therapeutics, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2020 $10.65M -64.4% 2018 $29.91M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ June 30, 2021 $10.73M +1.5% +0.4% March 31, 2021 $10.69M +1.1% … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Cash and Equivalents of $19.96 million for fiscal year 2025. Aclaris Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $19.96M -18.8% 2024 $24.57M -38.4% 2023 $39.88M -11.9% 2022 $45.28M +65.6% 2021 $27.35M +24.0% 2020 $22.06M -35.5% 2019 $34.19M +69.2% 2017 $20.20M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Total Assets of $160.46 million for fiscal year 2025. Aclaris Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $160.46M -27.2% 2024 $220.33M +11.6% 2023 $197.41M -22.5% 2022 $254.60M +1.3% 2021 $251.21M +254.9% 2020 $70.78M -28.0% 2019 $98.30M -64.3% 2018 $275.57M +13.2% 2017 $243.51M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Diluted EPS of $0.53 per share (loss) for fiscal year 2025. Aclaris Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.53 +69.0% 2024 -$1.71 -34.6% 2023 -$1.27 +4.5% 2022 -$1.33 +16.9% 2021 -$1.60 -33.3% 2020 -$1.20 +69.2% 2019 -$3.90 — Quarterly Diluted EPS … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Net Income of -$64.92 million for fiscal year 2025. Aclaris Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$64.92M +50.8% 2024 -$132.06M -49.3% 2023 -$88.48M -1.8% 2022 -$86.91M +4.4% 2021 -$90.86M -78.1% 2020 -$51.02M +68.4% 2019 -$161.35M -21.6% 2018 -$132.74M -93.7% 2017 -$68.52M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Revenue (ASC 606) of $7.83 million for fiscal year 2025. Aclaris Therapeutics, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $7.83M -58.2% 2024 $18.72M -40.1% 2023 $31.25M +5.0% 2022 $29.75M +340.1% 2021 $6.76M +4.3% 2020 $6.48M +53.3% 2019 $4.23M -31.3% 2018 $6.15M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Total Revenue of $7.83 million for fiscal year 2025. Aclaris Therapeutics, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $7.83M -58.2% 2024 $18.72M -40.1% 2023 $31.25M +5.0% 2022 $29.75M +340.1% 2021 $6.76M +4.3% 2020 $6.48M +53.3% 2019 $4.23M -31.3% 2018 $6.15M +265.5% 2017 $1.68M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Total Revenue of $7.83 million for fiscal year 2025. Aclaris Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $7.83M-58.2% $18.72M-40.1% $31.25M+5.0% $29.75M+340.1% $6.76M+4.3% $6.48M+53.3% Revenue (ASC 606) $7.83M-58.2% $18.72M-40.1% $31.25M+5.0% $29.75M+340.1% $6.76M+4.3% $6.48M+53.3% Net Income -$64.92M+50.8% -$132.06M-49.3% -$88.48M-1.8% -$86.91M+4.4% -$90.86M-78.1% -$51.02M+68.4% … Read more
Quick Answer Atacama Resources International, Inc. reported Shares Outstanding of 139.90 million shares for fiscal year 2016. Atacama Resources International, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2016 139.90M +22.5% 2015 114.21M +260.0% 2014 31.73M +1.0% 2013 31.40M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ June 30, … Read more
Quick Answer Atacama Resources International, Inc. reported Operating Income of -$833.2 thousand for fiscal year 2016. Atacama Resources International, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2016 -$833.2K -227.4% 2015 -$254.5K — Quarterly Operating Income Quarter Ending Operating Income YoY QoQ June 30, 2017 -$522.6K -164.0% -19.2% March 31, 2017 … Read more